Abstract：Bladder cancer is The most common urothelial cancer in China, whose incidence continues to increase.Urothelial carcinoma (UC) is the most frequent histopathologic type which represents more than 90% of the cases.UC is a chemotherapy-sensitive malignancy,cisplatin-based combination chemotherapy regimens like methotrexate,vinblastine,doxorubicin,and cisplatin (M-VAC),HD-MVAC or gemcitabine plus cisplatin (GC) are considered the standard therapy for patients with advanced carcinoma of the urothelium.In unfit patients,carboplatin based regimes like gemcitabine plus carboplatin or methotrexate plus carboplatin plus vinblastine (MCAVI) or carboplatin plus cisplatin (GCa) are reasonable options.This paper mainly reviews the research of chemotherapy for patients with advanced UC of the bladder.
[1]Jemal A, Bray F, Center MM,et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90. [2]Rathkopf D, Scher HI. Multidisciplinary Management of Genitourinary Malignancies in Malcolm R. Alison, editor. The cancer handbook. 2 edition. London: Jon Wiley & Son,2007:1432-52. [3]Cheung G,Sahai A,Billia M,et al. Recent advances in the diagnosis and treatment of bladder cancer.BMC Medilinc, 2013,11:13. [4]Hussain SA,James ND.The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol,2003,4(8):489-497. [5]Soloway MS, Einstein A, Corder MP,et al.A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer, 1983, 52(5):767-772. [6]Harke WG, Meyers FJ, Freiha FS,et al.Cisplatin, methotrexate,and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clinl Oncol, 1985, 1463-1470. [7]Troner M, Birch R, Omura GA,et al.Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol, 1987, 137(4):660-662. [8]Sternberg CN, Yagoda A, Scher HI,et al.Preliminary results of M-VAC (methotrexate, vinblastine,doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol, 1985, 133(3):403-407. [9]Logothetis CJ, Dexeus FH, Finn L,et al.A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol, 1990, 8(6):1050-1055. [10]Loehrer PJ, Einhorn LH, Elson PJ,et al.A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 1992,10(7):1066-1073. [11]Sternberg CN, de Mulder PH, Schornagel JH,et al.Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin,and cisplatin (MVAC)chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol, 2001, 19:2638-2646. [12]Sternberg CN, de Mulder P, Schornagel JH,et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer, 2006, 42:50-54. [13]Shorod ss,Faucette SR,Gillenwaler HH,el a1.Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.Cancer Chemother Pharmacol,2003,51:328. [14]Bellmunt J, Albiol S, de Olano AR,et al.Spanish Oncology Genitourinary Group (SOGUG). Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol, 2006,17:113-117. [15]Maase H,Hansen SW, Roberts JT,et al.Gemcitabine and cisplatin versus methotrexate, vinblastine,doxorubicin, and cisplatin in advanced or metastatic bladder cancer:results of a large, randomized, multinational, multicenter, phase Ⅲ study.J Clin Oncol, 2000, 18(17):3068-3077. [16]Maase H, Sengelov L, Roberts JT,et al.Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 2005, 4602-4608. [17]Dreicer R, Manola J, Roth BJ,et al.Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol, 2000, 18:1058-1061. [18]Dimopoulos MA, Bakoyannis C, Georgoulias V,et al.Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol, 1999, 10:1385-1388. [19]Small EJ, Lew D, Redman BG,et al.Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol, 2000, 18:2537-2544. [20]Vaughn DJ, Malkowicz SB, Zoltick B,et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol, 1998, 16:255-260. [21]Dreicer R, Manola J, Roth BJ,et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer, 2004, 100(8):1639-1645. [22]Bellmunt J, de Wit R, Albanell J,et al.A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer, 2001, 37:2212-2215. [23]De Santis M, Bellmunt J, Mead G,et al.Randomized phase II/III trial comparing gemcitabine/carboplatin (GC)and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy(CHT): Phase III results of EORTC study 30986. J Clin Oncol, 2010, 28:18s:abstract LBA4519. [24]Winquist E, Vokes E, Moore MJ,et al.A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol, 2005,23(3):150-154. [25]Meluch AA, Greco FA, Burris HA,et al.Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol, 2001, 19:3018-3024. [26]Stemberg CN,Calabro F, Pizzocaro G,et al.Chemotherapy with an every 2 week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have receivedprior cisplatin-based therapy.Cancer,2001,92 (12):2993 -2998. [27]Li J, Juliar B, Yiannoutsos C,et al.Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol, 2005, 23:1185-1191. [28]Li J, Juliar B, Yiannoutsos C,et al.Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol,2005, 23:1185-1191. [29]Dumez H, Martens M, Selleslach J,et al.Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs, 2007, 18:211-218. [30]Gitlitz BJ, Baker C, Chapman Y,et al.A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer, 2003, 98:1863-1869. [31]Pectasides D, Aravantinos G, Kalofonos H, et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.Ann Oncol, 2001,12(10):1417-2222. [32]Ricci S,Galli L,Chioni A,et al. Gemcitabine plu sepirubicinin patients with advanced urothelial carcinoma who arenoteligibleofr platinum-basedregimens.Cancer,2002,95(7):1444-1450. [33]Bellmunt J, Guillem V, Paz-Ares L,et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol, 2000, 18(18):324732-324755. [34]Bellmunt J, von der Maase H, Mead GM,et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol, 2007, 25,abstract LBA5030. [35]Bajorin DF, McCaffrey JA, Dodd PM,et al.Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer, 2000, 88:1671-1678. [36]Hussain M, Vaishampayan U, Du W,et al.Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol, 2001, 19:2527-33. [37]Pectasides D, Visvikis A, Aspropotamitis A,et al.Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eu J Cancer, 2000,36:74-79. [38]Milowsky MI, Nanus DM, Maluf FC,et al.Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol, 2009, 27(25):4062-4067. [39]Galsky MD, Iasonos A, Mironov S,et al.Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer, 2007,109(3):549-555.
